DPH Dechra Pharmaceuticals Plc

TIDMDPH

RNS Number : 0246A

Dechra Pharmaceuticals PLC

20 September 2022

20 September 2022

Dechra (R) Pharmaceuticals PLC

(the Company)

2022 Annual Financial Report

The Company announced its Preliminary Results on 5 September 2022 in accordance with the financial reporting obligations of the Disclosure and Transparency Rules.

Copies of the Annual Financial Report for the year ended 30 June 2022, Notice of Annual General Meeting and Proxy Form have today been mailed to shareholders.

In accordance with Listing Rule 9.6.1 a copy of the Annual Financial Report and Notice of Meeting has been submitted to the FCA document viewing facility https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

The Annual Financial Report, Notice of Annual General Meeting and information relating to the voting rights of Shareholders (as required by section 311A of the Companies Act 2006) are available to view on the Company's website www.dechra.com .

Further copies of the Annual Report are available from the Company's registered office at:

24 Cheshire Avenue

Cheshire Business Park

Lostock Gralam

Northwich

CW9 7UA

Enquiries:

Melanie Hall, Company Secretary

Dechra Pharmaceuticals PLC

Tel: +44 (0) 1606 814730

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide.

For more information please visit: www.dechra.com

LEI: 213800J4UVB5OWG8VX82

Trademarks

Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACSLMMJTMTJTBLT

(END) Dow Jones Newswires

September 20, 2022 09:41 ET (13:41 GMT)

Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024